Yiu Yin, Mahida Justin B, Cooper Jennifer N, Elsey Nicole M, Deans Katherine J, Minneci Peter C, Merrill Tyler B, Tobias Joseph D, Elmaraghy Charles A
Nationwide Children's Hospital, Department of Otolaryngology, Columbus, OH, USA.
Ohio State University Wexner Medical Center, Department of Surgery, Columbus, OH, USA.
Int J Pediatr Otorhinolaryngol. 2017 Jul;98:19-24. doi: 10.1016/j.ijporl.2017.04.033. Epub 2017 Apr 24.
Dexamethasone is currently recommended for routine prophylaxis against postoperative nausea and vomiting after tonsillectomy procedures. However, some studies have raised concern that dexamethasone use may lead to higher rates of post-tonsillectomy hemorrhage. Our objective was to determine whether higher doses of dexamethasone administered perioperatively during tonsillectomy procedures are associated with an increased risk of secondary post-tonsillectomy hemorrhage.
We conducted a retrospective review of 9843 patients who underwent tonsillectomy and received dexamethasone at our institution from January 2010 to October 2014. We compared the dose of dexamethasone administered to patients who did and did not develop secondary post-tonsillectomy hemorrhage using Mann Whitney U tests. Multivariable logistic regression models were used to evaluate the association between dexamethasone dose and post-tonsillectomy hemorrhage after adjustment for demographic and clinical characteristics.
A total of 280 (2.8%) patients developed secondary post-tonsillectomy hemorrhage. Patients who developed hemorrhage tended to be older (median (interquartile range) 7 (4-11) vs. 5 (3-8) years), p < 0.001) and had undergone tonsillectomy more often for chronic tonsillitis but less often for tonsillar or adenotonsillar hypertrophy or sleep disturbances. Dexamethasone dose was significantly lower on average in patients who experienced secondary post-tonsillectomy hemorrhage (median (interquartile range) 0.19 (0.14, 0.23) mg/kg vs. 0.21 (0.17, 0.30), p < 0.001). Multivariable modeling demonstrated that the dose of dexamethasone was not significantly associated with post-tonsillectomy hemorrhage after adjustment for age.
There does not appear to be a dose-related increase in the risk of post-tonsillectomy hemorrhage for patients receiving dexamethasone during tonsillectomy procedures.
目前推荐使用地塞米松常规预防扁桃体切除术后恶心和呕吐。然而,一些研究引发了人们对使用地塞米松可能导致扁桃体切除术后出血率升高的担忧。我们的目的是确定在扁桃体切除术中围手术期给予更高剂量的地塞米松是否与扁桃体切除术后继发性出血风险增加相关。
我们对2010年1月至2014年10月在我院接受扁桃体切除术并接受地塞米松治疗的9843例患者进行了回顾性研究。我们使用Mann-Whitney U检验比较了发生和未发生扁桃体切除术后继发性出血的患者所给予的地塞米松剂量。多变量逻辑回归模型用于评估在调整人口统计学和临床特征后地塞米松剂量与扁桃体切除术后出血之间的关联。
共有280例(2.8%)患者发生扁桃体切除术后继发性出血。发生出血的患者往往年龄较大(中位数(四分位间距)7(4 - 11)岁 vs. 5(3 - 8)岁,p < 0.001),因慢性扁桃体炎接受扁桃体切除术的频率更高,但因扁桃体或腺样体肥大或睡眠障碍接受手术的频率较低。经历扁桃体切除术后继发性出血的患者平均地塞米松剂量显著更低(中位数(四分位间距)0.19(0.14,0.23)mg/kg vs. 0.21(0.17,0.30),p < 0.001)。多变量建模表明,在调整年龄后,地塞米松剂量与扁桃体切除术后出血无显著关联。
在扁桃体切除术中接受地塞米松治疗的患者,扁桃体切除术后出血风险似乎不存在剂量相关的增加。